Question 1

What is AstraZeneca's P/E ratio?

Accepted Answer

AstraZeneca (AZN) P/E ratio is 12.8× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for AstraZeneca?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For AstraZeneca specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is AstraZeneca's P/E ratio high or low?

Accepted Answer

AstraZeneca's P/E ratio of 12.8× is below its own 5-year average of 64.9× and below the sector median of 24.2×. That places the current reading at the 1th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is AstraZeneca's historical P/E ratio range?

Accepted Answer

In the available daily series, AstraZeneca (AZN) P/E ratio has ranged from a low of 3.0× in 2011 to a high of 940.0× in 2022. The 5-year average is 64.9× and the 5-year median is 17.9×.

Question 7

What was AstraZeneca's P/E ratio in 2025?

Accepted Answer

AstraZeneca (AZN) P/E ratio at the end of 2025 was 13.3×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does AstraZeneca's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$136B	$10.2B	13.3×	-1.0×	Dec 31, 2025
2024	$101B	$7.04B	14.3×	-3.0×	Dec 31, 2024
2023	$103B	$5.96B	17.3×	-14.8×	Dec 31, 2023
2022	$106B	$3.29B	32.1×	-768.0×	Dec 31, 2022
2021	$89.6B	$112M	800.1×	+779.4×	Dec 31, 2021
2020	$66.3B	$3.2B	20.7×	-28.9×	Dec 31, 2020
2019	$66.3B	$1.34B	49.6×	+27.3×	Dec 31, 2019
2018	$48.1B	$2.16B	22.3×	+7.9×	Dec 31, 2018
2017	$43.4B	$3B	14.5×	+4.7×	Dec 31, 2017
2016	$34.1B	$3.5B	9.7×	-5.4×	Dec 31, 2016
2015	$42.8B	$2.83B	15.1×	-20.9×	Dec 31, 2015
2014	$44.4B	$1.23B	36.0×	+21.6×	Dec 31, 2014
2013	$36.9B	$2.56B	14.4×	+9.7×	Dec 31, 2013
2012	$29.4B	$6.25B	4.7×	+1.7×	Dec 31, 2012
2011	$30.4B	$9.98B	3.0×	-1.0×	Dec 31, 2011
2010	$32.7B	$8.05B	4.1×	-0.5×	Dec 31, 2010
2009	$34B	$7.52B	4.5×	-0.3×	Dec 31, 2009
2008	$29.7B	$6.1B	4.9×	-0.7×	Dec 31, 2008
2007	$31.2B	$5.6B	5.6×	-1.2×	Dec 31, 2007
2006	$40.7B	$6.04B	6.7×	-1.4×	Dec 31, 2006
2005	$38.4B	$4.71B	8.2×	+0.3×	Dec 31, 2005
2004	$30.1B	$3.81B	7.9×	-5.3×	Dec 31, 2004
2003	$40.1B	$3.04B	13.2×	+2.5×	Dec 31, 2003
2002	$30.1B	$2.83B	10.7×	—	Dec 31, 2002


Agilent Technologies (A)	23.1×
Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for AstraZeneca (AZN) 2002-2026

P/E Ratio daily chart for AstraZeneca (AZN)

Historical P/E Ratio for AstraZeneca (AZN) from 2002 to 2025

About P/E Ratio at AstraZeneca (AZN)

AstraZeneca P/E Ratio by Year

AstraZeneca P/E Ratio 2025: 13.3×

AstraZeneca P/E Ratio 2024: 14.3×

AstraZeneca P/E Ratio 2023: 17.3×

AstraZeneca P/E Ratio 2022: 32.1×

AstraZeneca P/E Ratio 2021: 800.1×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

AstraZeneca (AZN) Key Financials